Refractory Lymphomas Recruiting Phase 2 Trials for Trastuzumab (DB00072)

Also known as: Refractory Lymphoma

IndicationStatusPhase
DBCOND0042145 (Refractory Lymphomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs